EGFR and non-small cell lung carcinoma: More specific to TKI resistance, the two most accepted and recognized mechanisms in EGFR mutated NSCLC includes T790M point mutation in the EGFR kinase domain (which accounts about approximately 50%) and MET oncogene amplification (accounting about 20%) [46], [47].